RadNet, Inc. (NASDAQ:RDNT – Get Free Report) EVP Mital Patel sold 44,661 shares of the stock in a transaction dated Wednesday, November 11th. The shares were sold at an average price of $78.51, for a total transaction of $3,506,335.11. Following the completion of the sale, the executive vice president owned 155,514 shares of the company’s stock, valued at approximately $12,209,404.14. This represents a 22.31% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
RadNet Stock Down 2.6%
Shares of RDNT traded down $2.04 during trading hours on Thursday, reaching $76.04. 408,016 shares of the stock traded hands, compared to its average volume of 751,583. RadNet, Inc. has a 52 week low of $50.82 and a 52 week high of $85.84. The company has a market cap of $5.99 billion, a price-to-earnings ratio of 144.59 and a beta of 1.42. The stock has a fifty day simple moving average of $72.74 and a 200 day simple moving average of $65.49. The company has a current ratio of 1.49, a quick ratio of 1.48 and a debt-to-equity ratio of 0.90.
RadNet (NASDAQ:RDNT – Get Free Report) last issued its quarterly earnings data on Sunday, November 8th. The medical research company reported $0.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.22 by $0.08. RadNet had a negative net margin of 0.94% and a positive return on equity of 3.14%. The business had revenue of $638.26 million during the quarter, compared to the consensus estimate of $639.97 million. During the same period in the prior year, the firm posted $0.20 EPS. The firm’s quarterly revenue was up 22.1% compared to the same quarter last year. On average, equities analysts forecast that RadNet, Inc. will post 0.53 EPS for the current year.
Analyst Upgrades and Downgrades
A number of equities analysts have recently weighed in on the company. Barclays boosted their target price on RadNet from $65.00 to $79.00 and gave the stock an “overweight” rating in a research note on Friday, August 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of RadNet in a research report on Wednesday, November 4th. Truist Financial increased their price target on RadNet from $90.00 to $94.00 and gave the company a “buy” rating in a research report on Tuesday, August 11th. KeyCorp lifted their price target on RadNet from $92.00 to $95.00 and gave the stock an “overweight” rating in a report on Tuesday. Finally, Jefferies Financial Group reissued a “buy” rating on shares of RadNet in a research report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, RadNet presently has an average rating of “Moderate Buy” and a consensus price target of $90.43.
Read Our Latest Analysis on RadNet
Institutional Trading of RadNet
Large investors have recently added to or reduced their stakes in the stock. Hantz Financial Services Inc. raised its position in RadNet by 18.8% in the third quarter. Hantz Financial Services Inc. now owns 872 shares of the medical research company’s stock worth $60,000 after acquiring an additional 138 shares during the period. SteelPeak Wealth LLC grew its position in shares of RadNet by 0.6% during the 3rd quarter. SteelPeak Wealth LLC now owns 25,251 shares of the medical research company’s stock valued at $1,741,000 after acquiring an additional 151 shares during the period. Arizona State Retirement System grew its position in shares of RadNet by 0.9% during the 2nd quarter. Arizona State Retirement System now owns 18,203 shares of the medical research company’s stock valued at $1,123,000 after acquiring an additional 160 shares during the period. Oppenheimer & Co. Inc. increased its stake in shares of RadNet by 1.7% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 10,303 shares of the medical research company’s stock worth $710,000 after purchasing an additional 175 shares during the last quarter. Finally, PNC Financial Services Group Inc. increased its stake in shares of RadNet by 2.9% during the 1st quarter. PNC Financial Services Group Inc. now owns 7,392 shares of the medical research company’s stock worth $413,000 after purchasing an additional 207 shares during the last quarter. Hedge funds and other institutional investors own 77.90% of the company’s stock.
RadNet Company Profile
RadNet, Inc. operates outpatient diagnostic imaging centers in the United States. Its centers provide services including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), mammography, ultrasound, X-ray and nuclear medicine imaging. The company serves patients, physicians and healthcare organizations, with operations across several states, including California, Delaware, Florida, Maryland, New Jersey and New York. Its imaging centers offer diagnostic services for a range of medical needs, from routine screening to specialized examinations.
Featured Articles
- Five stocks we like better than RadNet
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Receive News & Ratings for RadNet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RadNet and related companies with MarketBeat.com's FREE daily email newsletter.
